Announcements Trials
Browse Landscape

Phase

Phase 2 7Phase NA 1

Status

Completed 4Recruiting 3

Sponsor Class

OTHER 6INDUSTRY 1

Study Type

Interventional 7

Sponsor

Cancer Type

Gastrointestinal 4Tumor-Agnostic 3

Conditions

Breast Neoplasms 303Stomach Neoplasms 34Neoplasm Metastasis 24Neoplasms 16Colorectal Neoplasms 16Breast Neoplasms, Male 16HER2-positive Breast Cancer 11Inflammatory Breast Neoplasms 10Triple Negative Breast Neoplasms 9Esophageal Neoplasms 9Carcinoma, Non-Small-Cell Lung 8Brain Neoplasms 8Rectal Neoplasms 7Adenocarcinoma 7Colonic Neoplasms 6Urinary Bladder Neoplasms 5Pathologic Complete Response 5Biliary Tract Neoplasms 5Urologic Neoplasms 4Salivary Gland Neoplasms 4Prostatic Neoplasms 4Lung Neoplasms 4Gallbladder Neoplasms 4Carcinoma, Ductal, Breast 4Recurrence 3Pancreatic Neoplasms 3Neoplastic Cells, Circulating 3Multiple Myeloma 3Meningeal Neoplasms 3HER2-positive Gastric Cancer 3

Interventions

Oxaliplatin 26Gemcitabine 22Fluorouracil 17Capecitabine 16Leucovorin 15pembrolizumab 14Docetaxel 14Cisplatin 13Bevacizumab 12Radiotherapy 8Paclitaxel 8Irinotecan 8Trastuzumab 7Pemetrexed 6Carboplatin 6130-nm albumin-bound paclitaxel 6durvalumab 5cemiplimab 5Erlotinib Hydrochloride 5Sunitinib 4Ramucirumab 4Metformin 4Gefitinib 4trastuzumab deruxtecan 3tislelizumab 3cabozantinib 3atezolizumab 3Taxes 3Sorafenib 3Panitumumab 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

7 trials
RecentStart dateEnrollment
Phase 2 × Adenocarcinoma × Trastuzumab × Clear all
NCT04379596 2026-05-13

DG-03

AstraZeneca

Phase 2 Recruiting
450 enrolled
Gastrointestinal

Adenocarcinoma, Carcinoma, Esophageal Neoplasms, Stomach Neoplasms

NCT05672524 2026-05-12

A Study of Tucatinib and Trastuzumab in People With Rectal Cancer

Memorial Sloan Kettering Cancer Center

Phase 2 Recruiting
37 enrolled
Gastrointestinal

Adenocarcinoma, Rectal Neoplasms

NCT04309578 2026-04-03

A Study of Trastuzumab in Combination With Capecitabine and Cisplatin in Patients With Tissue HER2- But Serum HER2+ AGC

Asan Medical Center

Phase 2 Completed
28 enrolled
Tumor-Agnostic

Adenocarcinoma

NCT06121700 2023-11-08

Miracle-G

Fudan University

Phase 2 Recruiting
55 enrolled
Gastrointestinal

Adenocarcinoma, Neoplasm Metastasis, Stomach Neoplasms

NCT02213289 2021-04-08

PANGEA-IMBBP: Personalized Antibodies for Gastro-Esophageal Adenocarcinoma - A 1st Pilot Metastatic Trial of Biologics Beyond Progression

University of Chicago

Phase 2 Completed
80 enrolled 14 charts
Tumor-Agnostic

Adenocarcinoma

NCT00515411 2019-12-10

Study of Modified Docetaxel, Cisplatin, and Fluorouracil (mDCF) in Unresectable or Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma

Memorial Sloan Kettering Cancer Center

Phase 2 Completed
111 enrolled 11 charts
Gastrointestinal

Adenocarcinoma, Stomach Neoplasms

NCT01472029 2017-06-19

HerFLOT

AIO-Studien-gGmbH

Phase 2 Completed
53 enrolled
Tumor-Agnostic

Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡